A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Tanguy Y. Seiwert(Georgetown University), Ezra E.W. Cohen(Moores Cancer Center), M. Degardin(Centre Hospitalier Universitaire de Nantes), Jérôme Fayette(Université Claude Bernard Lyon 1), Julie Cong(Boehringer Ingelheim (United States)), Alice Blackman(Boehringer Ingelheim (United States)), Flavio Solca(Boehringer Ingelheim (Austria)), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Paul M. Clément(Universitair Ziekenhuis Leuven), J.M. Tourani(Hôpital Laennec), J. M. Del-Campo(Vall d'Hebron Hospital Universitari)
Cited by 17
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994